Kyntra Bio, Inc. (KYNB)
6.30
+0.19
(+3.11%)
USD |
NASDAQ |
Oct 12, 15:14
Kyntra Bio Free Cash Flow (Quarterly) : -3.991M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.991M |
| March 31, 2026 | -13.89M |
| December 31, 2025 | -18.33M |
| September 30, 2025 | -1.856M |
| June 30, 2025 | 12.67M |
| March 31, 2025 | 2.657M |
| December 31, 2024 | -30.61M |
| September 30, 2024 | -8.458M |
| June 30, 2024 | -39.88M |
| March 31, 2024 | -59.32M |
| December 31, 2023 | -18.57M |
| September 30, 2023 | -85.22M |
| June 30, 2023 | -111.56M |
| March 31, 2023 | -102.18M |
| December 31, 2022 | -52.85M |
| September 30, 2022 | -52.74M |
| June 30, 2022 | -33.97M |
| March 31, 2022 | -10.11M |
| December 31, 2021 | -56.36M |
| September 30, 2021 | 42.68M |
| June 30, 2021 | -28.24M |
| March 31, 2021 | -45.50M |
| December 31, 2020 | -9.618M |
| September 30, 2020 | -1.768M |
| June 30, 2020 | 148.94M |
| Date | Value |
|---|---|
| March 31, 2020 | -59.94M |
| December 31, 2019 | -46.80M |
| September 30, 2019 | -29.29M |
| June 30, 2019 | -30.38M |
| March 31, 2019 | 22.00M |
| December 31, 2018 | -20.63M |
| September 30, 2018 | 7.091M |
| June 30, 2018 | -36.84M |
| March 31, 2018 | -33.81M |
| December 31, 2017 | -5.243M |
| September 30, 2017 | -21.89M |
| June 30, 2017 | -20.80M |
| March 31, 2017 | -28.11M |
| December 31, 2016 | -18.00M |
| September 30, 2016 | -1.99M |
| June 30, 2016 | 44.14M |
| March 31, 2016 | -18.29M |
| December 31, 2015 | -39.61M |
| September 30, 2015 | -38.80M |
| June 30, 2015 | 100.51M |
| March 31, 2015 | -42.64M |
| December 31, 2014 | -25.87M |
| September 30, 2014 | -33.12M |
| June 30, 2014 | 91.14M |
| March 31, 2014 | -17.85M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Vericel Corp. | 14.26M |
| Nektar Therapeutics | -75.86M |
| Capricor Therapeutics, Inc. | -37.39M |
| ARS Pharmaceuticals, Inc. | -60.93M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |